February 12th 2025
Your daily dose of the clinical news you may have missed.
January 29th 2025
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
January 29th 2025
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
January 17th 2025
The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.
July 19th 2024
Among GPs, IMs, FPs, the primary reason for reluctance to treat addiction is lack of support in the "institutional environment," followed by concerns over personal skills.
Highly Processed Food is Produced to Be as Rewarding as Humanly Possible, Says Food Addiction Expert
February 20th 2023Foods that are "engineered" with refined carbohydrates and fats that are rapidly absorbed can lead to cravings on par with those for alcohol and nicotine, says Ashley Gearhardt, PhD.
2 Commerce Drive
Cranbury, NJ 08512